Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Sun Pharma reported 9% year-on-year growth in consolidated sales for FY25, reaching 520,412 million.
- Q4 FY25 sales grew by 8.5% year-on-year, reaching 128,115.6 million.
- Specialty business contributed significantly to growth, offsetting declines in generics.
- India business maintained its market leadership with an 8.3% market share.
- The company launched a large-scale corporate branding campaign in India.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.